Gilead Sciences in the news

Gilead Sciences expanded licensing agreements for investigational once-yearly lenacapavir to support global manufacturing and supply for HIV prevention in 120 high-incidence countries.

Gilead Sciences partnered with the Pan American Health Organization to expand access to its HIV prevention drug, lenacapavir, in Latin America and the Caribbean, addressing a rise in new infections.

Gilead Sciences and the Pan American Health Organization are collaborating to improve access to lenacapavir for HIV prevention in Latin America and the Caribbean.

PAHO partnered with Gilead Sciences to expand access to the long-acting HIV prevention medicine lenacapavir in 14 Latin American and Caribbean countries.

Gilead Sciences partnered with the Pan American Health Organization to expand access to its HIV prevention drug, lenacapavir, across 14 Latin American and Caribbean countries.

Gilead Sciences powered the 2026 Atlanta Black Pride Weekend, a milestone celebration uniting the Black LGBTQ+ community for culture, visibility, wellness, and vital conversations around HIV prevention and health equity.

Gilead Sciences' CFO sold shares, the company reported quarterly earnings, declared a dividend, and expanded global access initiatives for its HIV prevention treatments.

Gilead Sciences' CEO stated that the company's oncology and inflammation expansion has reached a critical mass following a series of strategic acquisitions and significant investments in research and development facilities.

Gilead Sciences Inc. announced an upcoming $0.82 per share dividend and has consistently increased its quarterly payouts since 2015, underpinned by its focus on infectious disease and oncology therapies.

Gilead Sciences is prioritizing HIV, oncology, and inflammation pipeline execution, expanding prevention and treatment options while advancing new therapies in cancer.

Gilead Sciences sees substantial long-term growth in its HIV portfolio, driven by the successful launch of Sunlenca and ongoing pipeline advancements, while also expanding into inflammation and cell therapy.

Gilead Sciences and Nicole Byer launched "Care For The Culture" to encourage HIV testing and sexual health discussions in the Black community, which faces disproportionately high HIV rates.

Gilead Sciences is diversifying its portfolio beyond HIV into oncology and inflammation, while continuing to grow its core HIV franchise and managing upcoming pricing pressures.

Gilead Sciences opened a new 182,000-square-foot Research Center in Foster City, California, expanding its capabilities in oncology, inflammation, and data science as part of a $32 billion U.S. investment.

Gilead Sciences inaugurated a new 182,000 square-foot building for oncology and scientific research at its Foster City campus, with plans for further expansion.

Gilead Sciences opened a new research center at its Foster City headquarters to focus on drug discovery for oncology and inflammatory conditions.

Gilead Sciences opened a new 182,000-square-foot research center in Foster City to expand capabilities in oncology, inflammation, and data science.

Gilead Sciences opened a new 182,000 sq ft research center in California to develop new medicines and expand its R&D capabilities.

Gilead Sciences' investment story is evolving with the FDA approval of Bixlenvo for HIV, impacting its market position and financial outlook, alongside significant R&D expansion.

Assembly Biosciences will now co-share 40% of US development costs and profits for its herpes simplex virus program with Gilead Sciences, moving from a royalty-based deal.